{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:58:34Z","timestamp":1788893914754,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Several studies have indicated the benefits and safety of Endostar in combination with chemotherapy, but the exact real-life safety of Endostar is poorly known. This study aimed to assess the safety of Endostar in combination with chemotherapy in a real-life setting in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This was a retrospective study of patients treated with Endostar combined with chemotherapy from January 1, 2006, to December 31, 2017. Data were obtained from the Hospital Information System (HIS). Laboratory abnormalities were evaluated according to Common Terminology Criteria for Adverse Events, Version 4.0. Bleeding events and wound complications after surgery associated with Endostar were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Finally, 825 patients were included. No patients used Endostar alone. Anemia occurred in 74.5% of the patients, thrombocytopenia in 29.0%, abnormal white blood cell counts in 54.5%, abnormal liver function in 13.8%, and increased creatinine in 1.2%. No definite bleeding events and wound complications associated with Endostar were found. Most laboratory adverse effects (AEs) were found in Grades 1 and 2. Lung cancer, osteosarcoma, and doxorubicin-based chemotherapy were associated with an increased risk of Grade \u22653 abnormal white blood cell counts. The total dose of Endostar was not associated with severe (Grade \u22653) thrombocytopenia and abnormal white blood cell counts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The occurrence of AEs during Endostar and chemotherapy treatment differed across different tumor types and chemotherapy regimens. No new unexpected Endostar-related AEs were observed. The total dose of Endostar was not associated with an increased risk of severe (Grade \u22653) thrombocytopenia and abnormal white blood cell counts when used in combination with chemotherapy in the real-life setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijc.ijc_1065_20","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:04:38Z","timestamp":1739793878000},"page":"694-702","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Safety of Endostar in combination with chemotherapy in patients with cancer"],"prefix":"10.4103","volume":"61","author":[{"given":"Dong-Xiao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Peking University Shougang Hospital, Beijing, China"},{"name":"Department of Pharmacy, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai-Hong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University Shougang Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Wu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hong","family":"Zhao","sequence":"additional","affiliation":[{"name":"The State Key Laboratory of Translational Medicine and Innovative Drug Development, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"R1-20250217","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics. 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20250217","first-page":"XE01","article-title":"Tumour angiogenesis and angiogenic inhibitors: A review","volume":"9","author":"Yadav","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"R3-20250217","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/biomedicines5020034","article-title":"The role of angiogenesis in cancer treatment","volume":"5","author":"Rajabi","year":"2017","journal-title":"Biomedicines"},{"key":"R4-20250217","first-page":"687","article-title":"Tumor angiogenesis and anti-angiogenic gene therapy for cancer","volume":"16","author":"Li","year":"2018","journal-title":"Oncol Lett"},{"key":"R5-20250217","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: An endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O'Reilly","year":"1997","journal-title":"Cell"},{"key":"R6-20250217","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00432-012-1167-5","article-title":"Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer","volume":"138","author":"Liu","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"R7-20250217","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1158\/1538-7445.AM2016-2890","article-title":"Usefulness of dynamic contrast-enhanced magnetic resonance imaging for predicting treatment response to vinorelbine-cisplatin with or without recombinant human endostatin in bone metastasis of non-small cell lung cancer","volume":"6","author":"Zhang","year":"2016","journal-title":"Am J Cancer Res"},{"key":"R8-20250217","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/1759-7714.12626","article-title":"Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis","volume":"9","author":"An","year":"2018","journal-title":"Thorac Cancer"},{"key":"R9-20250217","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/2156587217730461","article-title":"Systematic review and meta-analysis of Endostar combined with transcatheter arterial chemoembolization (TACE) versus TACE alone for hepatocellular carcinoma","volume":"22","author":"Zhang","year":"2017","journal-title":"J Evid Based Complementary Altern Med"},{"key":"R10-20250217","doi-asserted-by":"crossref","first-page":"36716","DOI":"10.18632\/oncotarget.13545","article-title":"Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV","volume":"8","author":"Xing","year":"2017","journal-title":"Oncotarget"},{"key":"R11-20250217","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bone.2013.07.035","article-title":"Effects of Endostar combined multidrug chemotherapy in osteosarcoma","volume":"57","author":"Xu","year":"2013","journal-title":"Bone"},{"key":"R12-20250217","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11523-011-0204-7","article-title":"Cardiovascular toxicity of anti-angiogenic drugs","volume":"6","author":"des","year":"2011","journal-title":"Target Oncol"},{"key":"R13-20250217","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"R14-20250217","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"R15-20250217","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1477-7819-10-170","article-title":"Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer","volume":"10","author":"Rong","year":"2012","journal-title":"World J Surg Oncol"},{"key":"R16-20250217","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1186\/s12885-018-4738-2","article-title":"Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma","volume":"18","author":"Qin","year":"2018","journal-title":"BMC Cancer"},{"key":"R17-20250217","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1200\/jco.2010.28.15_suppl.7598","article-title":"Results of phase IV clinical trial of combining endostar with chemotherapy for treatment of advanced non-small cell lung cancer (NSCLC)","volume":"28","author":"Wang","year":"2010","journal-title":"J Clin Oncol"},{"key":"R18-20250217","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/JMDH.S160029","article-title":"Real world data: An opportunity to supplement existing evidence for the use of long-established medicines in health care decision making","volume":"11","author":"Katkade","year":"2018","journal-title":"J Multidiscip Healthc"},{"key":"R19-20250217"},{"key":"R20-20250217","doi-asserted-by":"crossref","first-page":"S626","DOI":"10.1016\/j.jtho.2018.08.968","article-title":"P1. 15-35 Real World Outcome of Different Administrations Endostar Combined With Chemotherapy in Driver Gene Mutation Negative Advanced NSCLC","volume":"13","author":"Zhang","year":"2018","journal-title":"J Thor Oncol"},{"key":"R21-20250217","doi-asserted-by":"crossref","first-page":"e12750","DOI":"10.1097\/MD.0000000000012750","article-title":"Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors","volume":"97","author":"Cheng","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R22-20250217","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e21019","article-title":"A real-world study of recombinant human endostatin continuous intravenous infusion combined with chemotherapy in the treatment of advanced mucosal melanoma","volume":"37","author":"Liu","year":"2019","journal-title":"J Clin Oncol"},{"key":"R23-20250217","doi-asserted-by":"crossref","first-page":"33926","DOI":"10.18632\/oncotarget.5271","article-title":"The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma","volume":"6","author":"Guan","year":"2015","journal-title":"Oncotarget"},{"key":"R24-20250217","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: A review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans"},{"key":"R25-20250217","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/14656566.4.6.889","article-title":"Toxicity of platinum compounds","volume":"4","author":"Hartmann","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"R26-20250217","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ajco.12771","article-title":"Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: A multicenter retrospective case-control study","volume":"14","author":"Yang","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"R27-20250217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2045-080X.174930","article-title":"A comparison between liposomal and nonliposomal formulations of doxorubicin in the treatment of cancer: An updated review","volume":"7","author":"Ngan","year":"2016","journal-title":"Arch Pharm Pract"},{"key":"R28-20250217","doi-asserted-by":"crossref","first-page":"31501","DOI":"10.18632\/oncotarget.8967","article-title":"The efficacy and safety of endostar combined with taxane-based regimens for HER-2-negative metastatic breast cancer patients","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_1065_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:27:02Z","timestamp":1787837222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_1065_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_1065_20","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2020-09-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}